- €1.89bn
- €2.83bn
- €1.16bn
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit
Brief: Dermapharm Confirms 2026 Guidance
Europe Research Roundup: HSBC, SMA Solar, ThyssenKrupp
Europe Research Roundup: HSBC, SMA Solar, ThyssenKrupp
Dermapharm Q1 revenue rises on branded pharmaceuticals growth, confirms 2026 outlook
Brief: Dermapharm Q1 Adjusted EBITDA EUR 87.4 Million
Brief: Dermapharm Holding - Q1 Consolidated Revenue Up 1.1% Y/Y To EUR 305.8 Mln
Brief: Dermapharm repurchases 4,299,190 shares
Brief: Dermapharm Holding SE - Resolves Public Share Buyback Offer For Up To 4,300,000 Shares
Germany's Dermapharm 2025 revenue slightly misses on portfolio adjustments in parallel import business
Brief: Dermapharm Holding FY Unadjusted EBITDA Up By 2.8%
Brief: Dermapharm FY Adjusted EBITDA EUR 324.8 Million
Brief: Dermapharm - Confirms Full-Year Guidance For 2025
Europe Research Roundup: Alfen, Dermapharm Holding, Fugro
Brief: Dermapharm Q2 EBITDA Up 3.7% In Q2 Versus Prior-Year Quarter
Brief: Dermapharm H1 Adjusted EBITDA EUR 148 Million